CVR Refining LP

10.49

0.0000

Volume:- -

Turnover:- -

Market Cap:1.55B

PE:3.78

High:10.49

Open:10.49

Low:10.49

Close:10.49

52wk High:26.00

52wk Low:8.30

Shares:147.60M

Float Shares:28.42M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):2.78

EPS(LYR):0.6016

ROE:--

ROA:--

PB:1.07

PE(LYR):17.44

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization

GlobeNewswire

·

Jan 09

Amarin Reports Second Quarter 2025 Financial Results

GlobeNewswire

·

Jul 30, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CVRR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CVRR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CVRR\",,,,,undefined,":{"symbol":"CVRR","market":"US","secType":"STK","nameCN":"CVR Refining LP","latestPrice":10.49,"timestamp":1575666000000,"preClose":10.49,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":28422136,"shares":147600000,"eps":2.776422,"marketStatus":"Delisted","change":0,"latestTime":"12-06 16:00:00 EST","open":10.49,"high":10.49,"low":10.49,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.776422,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1358398800000,"exchange":"NYSE","adjPreClose":10.49,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CVRR\",,,,,undefined,":{"symbol":"CVRR","floatShares":28422136,"roa":"--","roe":"--","lyrEps":0.601626,"shares":147600000,"dividePrice":0,"high":10.49,"amplitude":0,"preClose":10.49,"low":10.49,"week52Low":8.295,"pbRate":"1.07","week52High":26,"institutionHeld":0,"latestPrice":10.49,"eps":2.776422,"divideRate":0,"volume":0,"delay":0,"ttmEps":2.776422,"open":10.49},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CVRR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2018-11-02","symbol":"CVRR","amount":0.9,"name":"CVR Refining LP","currency":"USD","type":"dividend","dateTimestamp":1541131200000},{"market":"US","date":"2018-10-24","symbol":"CVRR","fiscalQuarterEnding":"2018/09","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1540353600000,"reportTimeType":"post","actualEps":1.18},{"market":"US","date":"2018-08-03","symbol":"CVRR","amount":0.66,"name":"CVR Refining LP","currency":"USD","type":"dividend","dateTimestamp":1533268800000},{"market":"US","date":"2018-07-25","symbol":"CVRR","fiscalQuarterEnding":"2018/06","expectedEps":0.75,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1532491200000,"reportTimeType":"post","actualEps":0.8},{"market":"US","date":"2018-05-04","symbol":"CVRR","amount":0.51,"name":"CVR Refining LP","currency":"USD","type":"dividend","dateTimestamp":1525406400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CVRR\",market:\"US\",,,undefined,":[{"executeDate":"2017-11-09","recordDate":null,"paymentDate":null,"value":0.94,"currency":"USD"},{"executeDate":"2018-03-02","recordDate":null,"paymentDate":null,"value":0.45,"currency":"USD"},{"executeDate":"2018-05-04","recordDate":null,"paymentDate":null,"value":0.51,"currency":"USD"},{"executeDate":"2018-08-03","recordDate":null,"paymentDate":null,"value":0.66,"currency":"USD"},{"executeDate":"2018-11-02","recordDate":null,"paymentDate":null,"value":0.9,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CVRR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CVRR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2602435373","title":"Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2602435373","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602435373?lang=en_us&edition=fundamental","pubTime":"2026-01-09 20:00","pubTimestamp":1767960000,"startTime":"0","endTime":"0","summary":"DUBLIN and BRIDGEWATER, N.J., Jan.  09, 2026  (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company advancing the science of cardiovascular therapeutics worldwide, today commented on re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/09/3216008/18362/en/Amarin-Applauds-Breakthroughs-In-Therapies-For-Patients-With-Elevated-Triglycerides-Company-s-VASCEPA-VAZKEPA-Icosapent-Ethyl-Franchise-Well-Positioned-To-Benefit-Globally-From-Bro.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRN","CV","BK4153","BK4090","BK4139","TG","IPE","CVRR","BK4082"],"gpt_icon":0},{"id":"2555430030","title":"Amarin Reports Second Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2555430030","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555430030?lang=en_us&edition=fundamental","pubTime":"2025-07-30 19:00","pubTimestamp":1753873200,"startTime":"0","endTime":"0","summary":"-- European Partnership with Recordati Established to Maximize VAZKEPA in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Mont","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/30/3123910/18362/en/Amarin-Reports-Second-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPE","AMRN","BK4153","BK4139","BK4090","TG","CVRR"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CVRR\",params:#limit:6,delay:false,,,undefined,":[]}}